Angina

Clinical Trial Finder

Many patients with angina are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Evaluation of Coronary Artery Plaque Volume Progression/Regression and Safety of Alirocumab in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia

Conditions:   Hypercholesterolemia;   Acute Coronary Syndrome
Interventions:   Drug: alirocumab SAR236553;   Drug: atorvastatin;   Drug: rosuvastatin;   Drug: fenofibrate;   Drug: bezafibrate;   Drug: ezetimibe;   Drug: antiplatelets;   Drug: anticoagulants
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified November 2016

One-hour Troponin in a Low-prevalence Population of Acute Coronary Syndrome

Conditions:   Non-ST Elevation Myocardial Infarction;   Acute Coronary Syndrome;   Angina, Unstable;   NSTEMI - Non-ST Segment Elevation MI
Intervention:   Procedure: 1-hour hs-cTnT
Sponsors:   Oslo University Hospital;   University of Oslo
Recruiting - verified December 2016

Myocardial Ischemia and Transfusion

Conditions:   Myocardial Infarction;   Anemia
Intervention:   Biological: Red Blood Cell Transfusion
Sponsors:   Rutgers, The State University of New Jersey;   University of Pittsburgh;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified December 2016

Metabolomic Profile of Patients Undergoing Myocardial Perfusion SPECT

Condition:   Ischemic Heart Disease
Intervention:   Other: Non intervention
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Recruiting - verified December 2016

Trial of MiStent Compared to Xience in Japan

Condition:   Coronary (Artery); Disease
Interventions:   Device: MiStent (MT005) Coronary Artery Stent;   Device: Xience Coronary Artery Stent
Sponsors:   Micell Technologies;   Cardialysis BV;   ClinLogix. LLC
Recruiting - verified November 2016

Use of Different Diagnostic Coronary Catheters Over the Radial Access - the UDDC - Radial Trial

Condition:   Stable Coronary Heart Disease
Interventions:   Device: One-catheter concept;   Device: Standard catheter
Sponsor:   Charite University, Berlin, Germany
Active, not recruiting - verified November 2016

Comprehensive Treatment of Angina in Women With Microvascular Dysfunction

Conditions:   Angina Pectoris;   Coronary Microvascular Disease
Interventions:   Dietary Supplement: Diet;   Behavioral: Training;   Drug: Medication (with statin and ACE-inhibition)
Sponsors:   Bispebjerg Hospital;   University Hospital Bispebjerg and Frederiksberg;   Cambridge Weight Plan Limited
Not yet recruiting - verified November 2016

In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment - at the Time of Coronary Angiography - Affect Management Strategy, Hospital Costs and Outcomes?

Conditions:   Chest Pain;   Stable Angina;   Acute Coronary Syndrome;   Non ST Segment Elevation Acute Coronary Syndrome
Intervention:   Device: Routine Measurement of FFR
Sponsors:   University Hospital Southampton NHS Foundation Trust;   Liverpool Heart and Chest Hospital NHS Foundation Trust
Recruiting - verified December 2016

Statin Therapy In Patients With Vasospastic Angina

Conditions:   Angina Pectoris, Variant;   Statins, HMG-CoA
Interventions:   Drug: Atorvastatin;   Drug: Placebo
Sponsors:   Seung-Jung Park;   CardioVascular Research Foundation, Korea
Not yet recruiting - verified December 2016

Feasibility and Outcomes of Complete Coronary Revascularization Using BVS in All-comer Patients With Angina

Condition:   Angina
Intervention:   Device: Bioresorbable vascular scaffold (BVS) implantation
Sponsors:   International Foundation for Development of Medical Science and Education Healthy Heart;   KCRI
Recruiting - verified September 2016

Changes in Ischemia and Angina Over 1 Year Among ISCHEMIA Trial Screen Failures With no Obstructive CAD on Coronary CT Angiography

Conditions:   Microvascular Angina;   Angina Pectoris
Interventions:   Other: Quality of Life assessment;   Procedure: Stress imaging
Sponsors:   New York University School of Medicine;   Duke Clinical Research Institute;   Massachusetts General Hospital
Recruiting - verified December 2016

NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial

Condition:   Coronary Artery Disease
Interventions:   Device: NeoVas BCS;   Device: XIENCE PRIME EECSS
Sponsor:   Lepu Medical Technology (Beijing) Co.,Ltd
Active, not recruiting - verified December 2016

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

Condition:   Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions:   Drug: Epanova® (omega-3 carboxylic acids);   Drug: corn oil control
Sponsors:   AstraZeneca;   Cleveland Clinic Coordinating Center for Clinical Research (C5R);   Quintiles, Inc.
Recruiting - verified November 2016

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified November 2016

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Terminated - verified December 2016

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Terminated - verified December 2016

Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients

Condition:   Stable Coronary Artery Disease (CAD), Myocardial Infarction
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified December 2016

Heart Outcomes Prevention and Evaluation 4

Conditions:   Hypertension;   Cardiovascular Disease
Interventions:   Other: Intervention;   Other: Usual Care
Sponsors:   Hamilton Health Sciences Corporation;   Population Health Research Institute;   Canadian Institutes of Health Research (CIHR);   Grand Challenges Canada;   Global Alliance for Chronic Diseases
Recruiting - verified November 2016

An Efficacy and Outcome Study of Supplemental Oxygen Treatment in Patients With Suspected Myocardial Infarction

Conditions:   Acute Coronary Syndrome;   Non-ST Elevation (NSTEMI) Myocardial Infarction;   Acute ST Segment Elevation Myocardial Infarction;   Angina, Unstable
Intervention:   Drug: Oxygen
Sponsors:   Karolinska Institutet;   Swedish Heart Lung Foundation;   Swedish Foundation for Strategic Research;   The Swedish Research Council
Active, not recruiting - verified December 2016

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab;   Drug: Placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified December 2016

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Coronary Artery Disease;   Heart Diseases;   Myocardial Ischemia
Interventions:   Procedure: cardiac catheterization;   Procedure: coronary artery bypass graft surgery;   Procedure: percutaneous coronary intervention;   Behavioral: Lifestyle;   Drug: Medication
Sponsors:   New York University School of Medicine;   New York University;   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI);   Albany Stratton VA Medical Center;   Cedars-Sinai Medical Center;   Columbia University;   Duke University;   East Carolina University;   Emory University;   Harvard University;   Massachusetts General Hospital;   Montreal Heart Institute;   University of British Columbia;   University of Missouri, Kansas City;   Vanderbilt University
Recruiting - verified December 2016

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Condition:   Atherosclerosis
Interventions:   Drug: Canakinumab;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Active, not recruiting - verified December 2016

Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression

Conditions:   Atherosclerosis;   Hypercholesterolemia
Interventions:   Drug: Statin Drugs;   Other: HMG-CoA Reductase Inhibitors
Sponsor:   National Institutes of Health Clinical Center (CC)
Active, not recruiting - verified March 2016